Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021
News | Coronavirus (COVID-19)
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

Home May 18, 2021
Home
Videos | Robotic Systems
VIDEO: Interventional Stroke Care May be Aided by Robotic Cath Lab Telemedicine

Ehtisham Mahmud, M.D., division chief of cardiovascular medicine, director of interventional cardiology and the cardiac ...

Home May 18, 2021
Home
Videos | Robotic Systems
VIDEO: Robotic PCI Performed Well in Real-world Population in the PRECISION GRX Study

Ehtisham Mahmud, M.D., division chief of cardiovascular medicine, director of interventional cardiology and the cardiac ...

Home May 18, 2021
Home
This trial used a therapeutic hypothermia system that used balloon catheters filled with cooled saline, such as the Zoll Thermogard XP temperature management system. #ACC21 #ACC2021 #therapeutichypothermia
News | Sudden Cardiac Arrest
Lower Temperature Therapeutic Hypothermia Did Not Improve Outcomes After Cardiac Arrest

May 17, 2021 — In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who ...

Home May 17, 2021
Home
The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.
News | Peripheral Artery Disease (PAD)
Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
The FLOWER-MI trial presented at ACC 2021 found no benefit to FFR-guided PCI in STEMI with multi-vessel disease. #ACC21 #ACC2021 #FFR
News | FFR Technologies
No Benefit to FFR-guided PCI in STEMI Patients With Multi-Vessel Disease

May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack ...

Home May 17, 2021
Home
DAIC magazine won Overall Excellence Finalist/Multi-platform Package of the Year for its coverage of the COVID-19 Pandemic’s Toll on Cardiology, National. The entry won an honor mention for its coverage of the COVID pandemic. Dave Fornell is the editor of DAIC.
Feature | Diagnostic and Interventional Cardiology DAIC | By Melinda Taschetta-Millane
DAIC Brings Home National, Regional Honors

Diagnostic and Interventional Cardiology (DAIC) and its sister publication Imaging Technology News (ITN) recently took ...

Home May 17, 2021
Home
The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN
Feature | Hypertension | By Dave Fornell, Editor
Renal Denervation Lowers Blood Pressure in Medication-Resistant Hypertension 

May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...

Home May 16, 2021
Home
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 
Feature | EP Lab | By Dave Fornell, Editor
Etripamil Nasal Spray Reduced ER Vistsis and More PSVT Resolution in New NODE-301 Analysis

May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...

Home May 16, 2021
Home
The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman
Feature | Left Atrial Appendage (LAA) Occluders
NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

Home May 16, 2021
Home
The mechanism of action for mavacamten, a cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (oHCM). EXPLORER-HCM trial #ACC21 #ACC2021
News | Pharmaceuticals
Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

Home May 15, 2021
Home
The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021
News | Heart Failure
Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack

May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...

Home May 15, 2021
Home
In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021
News | Left Atrial Appendage (LAA) Occluders
Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

Home May 15, 2021
Home
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021
News | Antiplatelet and Anticoagulation Therapies
Baby and Regular Strength Aspirin Equal in Cardiac Platelet Inhibition and Safety

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.
News | Structural Heart
TAVR Anticoagulation With Apixaban Not Superior to Standard Care

May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic ...

Home May 15, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now